Feed aggregator

Prediction: This Data Center REIT Could Double as AI Demand Soars

Top Stories - Sun, 12/21/2025 - 08:25

The Secret to Finding the Next Broadcom Is Hiding in Plain Sight

Top Stories - Sun, 12/21/2025 - 08:20

Ellison’s hardball Warner Bros. tactics gave Netflix an opening

Top Stories - Sun, 12/21/2025 - 08:00

Advisors Target Diversification in 2026 Strategies as Mag 7 Risk Rises

Top Stories - Sun, 12/21/2025 - 08:00

After my divorce I ended up with a truck $7K underwater. Here are the best ways to manage your debt

Top Stories - Sun, 12/21/2025 - 07:45

Stocks enter final stretch of 2025 just off record highs: What to watch this week

Top Stories - Sun, 12/21/2025 - 07:41

Coty Completes Wella Divestment to Refocus on Fragrances

Top Stories - Sun, 12/21/2025 - 07:40

Denison Mines Forms Joint Ventures With Skyharbour

Top Stories - Sun, 12/21/2025 - 07:40

Jefferies Sees Structural Strength but Limited Upside for UWM Holdings Corporation (UWMC)

Top Stories - Sun, 12/21/2025 - 07:40

Wall Street Keeps B2Gold Corp. (BTG) in Focus With Mixed Views

Top Stories - Sun, 12/21/2025 - 07:40

BlackBerry Limited (BB) Outperforms Estimates but RBC Sticks With Sector Perform

Top Stories - Sun, 12/21/2025 - 07:40

Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy?

Top Stories - Sun, 12/21/2025 - 07:40

NIO Inc. (NIO) Holds Mixed Analyst Sentiment Despite Strong Median Upside Potential

Top Stories - Sun, 12/21/2025 - 07:40

Clarivate Plc (CLVT) Downgraded Amid Turnaround Challenges

Top Stories - Sun, 12/21/2025 - 07:40

Cosan S.A. (CSAN) Gets Negative Outlook from Fitch as Leverage Remains High

Top Stories - Sun, 12/21/2025 - 07:35

Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study

Top Stories - Sun, 12/21/2025 - 07:31

Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program

Top Stories - Sun, 12/21/2025 - 07:31

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin

Top Stories - Sun, 12/21/2025 - 07:31

Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data

Top Stories - Sun, 12/21/2025 - 07:31

Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR)

Top Stories - Sun, 12/21/2025 - 07:31
Syndicate content
 
Worldstockexchange® Information Center